Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
NCT01263691
Completed
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reac... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +2 locations
Conditions: Bacillus Anthracis (Anthrax) Infection
Register for Updates
Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
NCT01311674
Terminated
Hepatitis B Virus Antibody Booster Program
Gender:
ALL
Ages:
Between 20 years and 55 years
Trial Updated:
03/14/2024
Locations: Cangene Plasma Resources, Mid-Florida, Altamonte Springs, Florida +1 locations
Conditions: Healthy Volunteers
Register for Updates
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
NCT00053482
Completed
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
Gender:
ALL
Ages:
28 years and above
Trial Updated:
03/14/2024
Locations: PRA International, Lenexa, Kansas +2 locations
Conditions: Smallpox
Register for Updates
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
NCT01770743
Completed
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Miami Research Associates, Miami, Florida +3 locations
Conditions: Anthrax
Register for Updates
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
Completed
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/01/2024
Locations: Benchmark Research, Austin, Texas +4 locations
Conditions: COVID-19
Register for Updates
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
NCT02545868
Completed
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/29/2024
Locations: North Central Neurology Associates, Cullman, Alabama +21 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
NCT04062669
Completed
The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM \[CNE\] vaccine), made using a new technology, when administered intramuscularly (IM) on a 0, 2, 6 \*-month schedule to healthy adults. \* There will be no vaccinations with the third dose of any of the study treatments.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
02/29/2024
Locations: GSK Investigational Site, South Miami, Florida +3 locations
Conditions: Virus Diseases
Register for Updates
Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
NCT03771157
Completed
The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/16/2024
Locations: University of Rochester, Rochester, New York
Conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Register for Updates
Solid Organ Transplant SHINGRIX
NCT03993717
Terminated
This study will assess the immune responses to the recombinant, AS01-adjuvanted varicella zoster virus subunit (HZ/su) vaccine or SHINGRIX in immunosuppressed patients, particularly those who have received a renal transplant, and aim to better understand if the vaccine and perhaps other adjuvanted vaccines are safe in these patients. 30 participants will be divided into 2 groups, one group will receive the 1st out of 2 doses of the vaccine 3-6 months after transplant per standard of care and th... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/15/2024
Locations: Hope Clinic, Atlanta, Georgia +3 locations
Conditions: Kidney Transplant; Complications
Register for Updates
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
NCT03604406
Active Not Recruiting
This investigator-initiated study will serve as a sub-study for the American College of Rheumatology-sponsored VERVE protocol currently funded by the NIH. This double-blinded multicenter randomized pragmatic trial is designed to determine whether Zostavax or Shingrix are safe and effective in patients with rheumatoid arthritis (RA) currently using anti-tumor necrosis factor (TNF) therapies. Inclusion/exclusion criteria for this sub-study mirror that of the parent VERVE trial with the exception o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: St. Luke's Health System, Boise, Idaho +4 locations
Conditions: Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Register for Updates
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
NCT05543642
Active Not Recruiting
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: Center for Rheumatic Diseases, Northport, Alabama +12 locations
Conditions: Rheumatic Diseases
Register for Updates
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
NCT03530124
Completed
A prospective, randomized open-label clinical trial will be conducted from July 2018 to October 2020. Approximately 300 preterm infants will be enrolled across three sites: Duke University Medical Center, the University of North Carolina, and Cincinnati Children's Hospital Medical Center. Eligible infants will be randomized 1:1 to receive either 2-month US licensed childhood vaccines (PCV13, DTaP, HBV, IPV an Hib) or no vaccines. After their participation in the study, healthcare providers of th... Read More
Gender:
ALL
Ages:
6 weeks and above
Trial Updated:
02/12/2024
Locations: Centers for Disease Control and Prevention, Atlanta, Georgia +3 locations
Conditions: Apnea, Apnea Neonatal, Prematurity
Register for Updates